Floatz logo

Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine

Chronic Myeloid Leukemia

City of Hope Medical CentervaccinePhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

77 Active assets in the Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Methotrexate
M.D. Anderson Cancer Center
Phase 3BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB

View all 50 →

Same molecule, other indications

Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine is also rated in:

hematopoietic and lymphoid cell neoplasmActive
B
Indicative · Phase 2
60 / 100
View asset →
myeloproliferative neoplasmActive
CCC
Indicative · Phase 2
54 / 100
View asset →
acute lymphoblastic leukemiaActive
CCC
Indicative · Phase 2
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →